{"schema_version":"secwatch.filing_event.v1","accession":"0000014272-22-000164","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2022-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.705392+00:00","generated_at":"2026-06-24T08:05:44.237276+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bristol-Myers Q2 revenue $11.9B (+2% YoY); Non-GAAP EPS $1.93 (+18%); GAAP EPS guidance adjusted","bullets":["Q2 revenue $11.887B, up 2% (5% ex-FX); U.S. revenue +12% to $8.3B, international revenue -16% (-8% ex-FX).","GAAP EPS $0.66 (up 40%); non-GAAP EPS $1.93 (up 18%); GAAP net earnings $1.4B vs $1.1B.","In-line product revenue +11% YoY (Eliquis +16%, Opdivo +8%); Revlimid -22% on generic erosion.","New product portfolio added $257M (Abecma, Opdualag, Reblozyl); Acquired IPRD charges $400M.","2022 GAAP EPS guidance adjusted; non-GAAP EPS guidance reaffirmed; dividend maintained at $0.54/share."],"urls":{"canonical":"https://secwatch.observer/filing/0000014272-22-000164","json":"https://secwatch.observer/filing/0000014272-22-000164.json","markdown":"https://secwatch.observer/filing/0000014272-22-000164.md","text":"https://secwatch.observer/filing/0000014272-22-000164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000001427222000164/0000014272-22-000164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000001427222000164/bmy-20220727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:05:44.237276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}